October in Overdrive: Inside Optimum’s 18th Annual Healthcare Investor Conference
Save the date: Optimum’s 19th Annual Healthcare Investor Conference — 7 October 2027. We look forward to seeing you there!
📸 Were you there? Find your photos and have your say!
Find your photos, download your favourites and share them on social media, and don’t forget to tag Optimum so we can see them too. Please also take part in our short feedback survey – it really helps the event to thrive, year on year.
🔗👉 [PARTICPATE IN THE FEEDBACK SURVEY]
🔗👉 [VIEW THE CONFERENCE PHOTO GALLERY]
If you encounter any issues downloading, it may be due to your company’s firewall settings. In that instance – we recommend trying a different, or personal, device!
Thank you to our generous sponsors — Babraham Research Campus, Barclays, Citi, Cooley, Domainex, Gilmartin Group, M Ventures, Nasdaq and Oppenheimer – for their support.
Lastly, to our guests, thank you again for being part of the day. Stay tuned for post-conference content and future event updates on our website and social channels.
Â
————————————————————————————————–
RougeTx launched with a $58 Million Series A Financing to advance its first-in-class treatment for Hereditary Hemorrhagic Telangiectasia. The round was co-led by founding investor BioGeneration Ventures (BGV) with Angelini Ventures, together with EIB (European Investment Bank) co-investment facility Aurea, and Kurma Partners, with further participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest, and Kerna Ventures. Financing will advance a potential once-daily oral treatment designed to restore blood vessel stability in HHT, a serious inherited bleeding disorder with no approved therapies.
Rewind Therapeutics secured additional financing to advance development of its lead GPR17 antagonist programme, a potential disease-modifying oral therapy intended to promote remyelination and restore neurological function in multiple sclerosis (MS).
Poolbeg Pharma announced that a South Korean patent has been granted for POLB001 in cancer immunotherapy-induced CRS. The Patent further strengthens POLB 001’s global intellectual property portfolio, enhancing its attractiveness to potential partners as it progresses through the clinic in the ongoing TOPICAL trial.
Resolution Therapeutics announced it will present interim Phase I/II EMERALD study data on RTX001, its engineered Regenerative Macrophage Therapy, as a late-breaker at AASLD 2026 – The Liver Meeting® 2026, being held in Denver, Colorado from 5–9 November 2026.
iOnctura announced the publication of two peer-reviewed articles in Nature Communications revealing new insights into the novel mechanism and clinical profile of roginolisib, the company’s next-generation, conformation-selective PI3Kδ inhibitor. Together, findings from these studies mark a promising new chapter for PI3Kδ inhibition.
BIO-Europe’s Biopharma C-Suite Agenda Survey 2026 is now live! The report captures the views of 81 senior biopharma executives on the trends shaping dealmaking, investment, AI and innovation. The findings reveal  an industry balancing greater confidence with continued constraint – 🔗download here.
Congratulations to Freya Biosciences named as one of Fierce Biotech’s “Fierce 15” for 2026 – the recognition reflects Freya’s scientific progress and commitment to addressing significant unmet needs in women’s health.
đź‘ĄIndustry events
BIO-Europe 2026 – Cologne, Germany | 9–11th Nov 2026
Connecting with the global biotech community – Our CEO, Mary Clark, and Associate Director Zoe Bolt will be attending BIO-Europe 2026, one of the leading international dealmaking events for the life sciences industry.
The team are looking forward to meeting with companies, investors and potential partners to discuss collaboration opportunities. Get in touch to schedule a get-together.
Jefferies Global Healthcare Conference & London Life Sciences Week – London | 15–20th Nov 2026Â
Optimum Strategic Communications and Catalyst Advisors LP, in partnership with Jefferies, are producing the official Networking Event Guide, helping attendees discover the key receptions, workshops, panels and gatherings taking place throughout the week.
đź”— Register to receive the guide when it launches on 13 October: [link]
Â
London Landmarks Run | 17 November 2026
Optimum Strategic Communications and Catalyst Advisors LP will be hosting a 5K #LondonLandmarksRun during the #Jefferies Global Healthcare Conference and London Life Sciences Week this November.
🕰️ ~7.00am GMT
đź”— Register for more information: https://lnkd.in/eAXkyvBF
Sponsorship Opportunities – Anglonordic Europe Life Science Conference
Looking to raise your visibility among Europe’s life sciences decision-makers?
Sponsorship opportunities for the 23rd Anglonordic Europe Life Science Conference are now available. Showcase your expertise, strengthen your brand and connect with investors, partners and industry leaders driving the future of the sector.
đź“© Contact anglonordic@optimumcomms.com to explore sponsorship packages
đź”— Learn more: Sponsorship opportunities
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
